Results 231 to 240 of about 123,739 (297)

Cell membrane‐coated nanoparticles for dermatological diseases

VIEW, EarlyView.
Skin disorders are challenging to treat due to complex barrier functions and limited conventional therapies. Biomimetic cell membrane‐coated nanoparticles (CM‐NPs) offer a superior nanomedicine approach by evading immune detection and enabling precise targeting.
Shuaijun Zou, Baojie Zhang, Yuanjie Zhu
wiley   +1 more source

Photodynamic Therapy Combined with Surgery: An Effective Treatment for Keloids via the YAP/Engrailed-1 Signaling Pathway. [PDF]

Clin Cosmet Investig Dermatol
Ren Y, Zhang J, Jiang H, Wang Y, Lu Y.
europepmc   +1 more source

Staging concept for aging management: Definition, mechanism, and coping strategies

VIEW, EarlyView.
We divided the overall aging stage into “pre‐aging”, “aging compensation”, and “aging disability”. For each stage, we delineate the clinical presentations, biological phenomena, theoretical underpinnings, and key management priorities. Abstract Aging, as a gradual and largely irreversible biological process, characterized by declining organismal ...
Zhonghan Wang, Shixian Liu, Shangyu Du, Xiangran Cui, Bo Chao, Minglei Liu, Minfei Wu   +6 more
wiley   +1 more source

Cold atmospheric plasma degrades methylene blue and shifts bacterial inactivation during photodynamic therapy. [PDF]

Sci Rep
Baek KH, Park JY, Yoon YB, Choi J, Jung S, Choi YJ, Choi MJ, Yong HI, Lee S.   +8 more
europepmc   +1 more source

Enterococcus faecalis and Endodontic Treatment Failure: A Qualitative Systematic Review of Its Role and Elimination Strategies

Australian Endodontic Journal, EarlyView.
ABSTRACT The aim of this study was to synthesize evidence on the influence of Enterococcus faecalis on endodontic treatment failure and strategies for its elimination. This study followed the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines and was registered in PROSPERO (CRD420251022741).
Francine Santos Fernandes de Lima, Analia Gabriella Borges Ferraz Facury   +1 more
wiley   +1 more source

Risk factors for the development of subretinal fluid in the fellow eyes of patients with chronic central serous chorioretinopathy

Acta Ophthalmologica, EarlyView.
Abstract Purpose To assess the risk of subretinal fluid (SRF) development in the fellow eye of chronic central serous chorioretinopathy (cCSC) patients with unilateral SRF at baseline. Methods Medical records of 334 presumed cCSC patients were retrospectively reviewed.
Helena M. A. Feenstra, Tahir Cakar, Joost Brinks, Camiel J. F. Boon, Elon H. C. van Dijk   +4 more
wiley   +1 more source

Comparative Efficacy of Photodynamic Therapy Versus Cryotherapy for Actinic Keratosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

J Cosmet Dermatol
Aldraibi S, Alharbi M, Alzubaidi K, Turkistani O, Kassim AB, Almutairi D, Alhammadi M, Makhtoum J, Alghamdi F.   +8 more
europepmc   +1 more source

Long‐term follow‐up of chronic central serous chorioretinopathy patients receiving oral eplerenone and half‐dose photodynamic therapy in the SPECTRA trial: SPECTRA trial report No. 4

Acta Ophthalmologica, EarlyView.
Abstract Purpose Assessing the 24‐month treatment outcome of half‐dose photodynamic therapy (PDT) or oral eplerenone in chronic central serous chorioretinopathy (cCSC). Methods Multicentre randomized clinical trial included cCSC patients from the SPECTRA trial who were randomized to receive half‐dose PDT or oral eplerenone.
Helena M. A. Feenstra, Issam El Mansori, Thomas J. van Rijssen, Roula Tsonaka, Roselie M. H. Diederen, Carel B. Hoyng, Reinier O. Schlingemann, Camiel J. F. Boon, Elon H. C. van Dijk   +8 more
wiley   +1 more source

Effect of Photosensitiser Chlorin E6 on Cancerous Bone Tumor Cells Using Photodynamic Therapy. [PDF]

Oncol Res
Traub F, Panezai MA, Moisch M, Melke J, Schöbel L, Busse T, Xing F, Sun J, Ritz U.   +8 more
europepmc   +1 more source

Focal therapy using a novel cooled laser device for prostate cancer: early trial results

BJU International, EarlyView.
Objectives To determine the short‐term oncological results and safety of the ProFocal Laser Therapy for Prostate Tissue Ablation (PFLT‐PC) trial, the first phase II clinical trial of ProFocal® (Medlogical Innovations, Sydney, Australia), a novel, cooled laser focal therapy (cLFT) device for prostate cancer (PCa) treatment. Patients and Methods Men with
Jonathan Kam, Bishoy Hanna, Stuart Jackson, Stephen McCombie, George McClintock, Matthew J. Roberts, Jake Rahkala, Jeremy Teoh, Mohan Arianayagam, Bertram Canagasingham, Ahmed Saeed Goolam, Nicola Jeffery, Matthew Winter, Mohamed Khadra, Raymond Ko, Nicholas Mehan, Isaac Thangasamy, Celi Varol   +17 more
wiley   +1 more source